IP Library › Granted Patent US 12,280,110
Granted Patent B2
US 12,280,110 · App. 17/889,875 · Granted Apr 22, 2025

Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM

Inventors: Thomas Barnett (Chapel Hill, NC); David A. Ross (Cary, NC)
Assignee: Grifols Worldwide Operations Limited
A61K39/40A01K67/0275C07K16/00C07K16/1214C07K16/1228C07K16/1232C07K16/1282C07K2317/52C07K2317/70C07K2317/73C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,110
App. No.
17/889,875
Granted
Apr 22, 2025
Kind
B2
Abstract

Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.

Claims (14)

1. A composition comprising at least 5 mg/mL isolated IgM and a pharmaceutically acceptable carrier, wherein the composition has at least 95% (w/v) of IgM purity and wherein IgG has been removed, wherein the pharmaceutically acceptable carrier is petroleum, peanut oil, soybean oil, mineral oil, sesame oil, polyethylene glycol, glycerin, propylene glycol, aqueous dextrose, a glycerol solution, or an excipient, wherein the excipient is selected from the group consisting of starch, gelatin, silica gel, sodium stearate, glycerol monostearate, talc, glycerol, propylene glycol, a wetting or emulsify agent, or a combination thereof.

2. The composition according to claim 1 , characterized in that IgM is recombinant.

3. The composition according to claim 1 , characterized in that IgM is plasma-derived.

4. The composition according to claim 1 , characterized in that IgM is cell culture-derived.

5. The composition according to claim 1 , characterized in that IgM is transgenic.

6. The composition according to claim 1 , characterized in that IgM is chemically synthesized.

7. The composition according to claim 3 , wherein IgM is plasma-derived IgM and is isolated from a suitable fraction of plasma.

8. The composition according to claim 1 , characterized in that the composition further comprises one or more anti-inflammatory molecules, small molecule antibiotics, molecules that are antimicrobial in nature, natural or synthetic peptide antimicrobials, proteins with antimicrobial properties, other immunomodulators or combinations thereof.

9. The composition according to claim 8 , wherein the composition further comprises vancomycin, meropenem, lactoferrin or combinations thereof.

10. The composition according to claim 1 , wherein IgM is enriched against an exotoxin, secreted protein, microbial species, or combination thereof.

11. The composition according to claim 1 , wherein the pharmaceutically acceptable carrier is synthetic.

12. The composition according to claim 1 , wherein the pharmaceutically acceptable carrier is a diluent, an excipient, an adjuvant, or a vehicle.

13. The composition according to claim 1 , wherein the wetting or emulsifying agent is selected from the group consisting of benzyl alcohol, methyl parabens, sodium bisulfite, ethylenediaminetetraacetic acid, or dextrose.

14. The composition of according to claim 1 , wherein the composition further comprises vancomycin, meropenem, or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: BARNETT, THOMAS; ROSS, DAVID A.
To: GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 061597/0550 →
Continuity (6)
Continuation 16849083 · Apr 15, 2020
Continuation 16456689 · Jun 28, 2019
Continuation 15883486 · Jan 30, 2018
Division 15147226 · May 5, 2016
Provisional Application 62201917 · Aug 6, 2015
Related Publication 20230077855A1 · Mar 16, 2023
References Cited (58)
US 4652533A · Jolley · 1987 [cited by examiner]
US 4714681A · Reading · 1987 [cited by examiner]
US 4918163A · Young et al. · 1990 [cited by applicant]
US 5190752A · Möller et al. · 1993 [cited by applicant]
US 5410025A · Moller et al. · 1995 [cited by applicant]
US 6307028B1 · Lebing et al. · 2001 [cited by applicant]
US 7794721B2 · Simon · 2010 [cited by applicant]
US 9913903B2 · Barnett et al. · 2018 [cited by applicant]
US 20030185827A1 · Rodriguez et al. · 2003 [cited by applicant]
US 20060233781A1 · Pedersen · 2006 [cited by examiner]
US 20080145370A1 · Simon et al. · 2008 [cited by applicant]
US 20080317857A1 · Farina et al. · 2008 [cited by applicant]
US 20090298789A1 · Dobson · 2009 [cited by examiner]
US 20100297187A1 · Stoloff et al. · 2010 [cited by applicant]
US 20100303897A1 · Jerecic · 2010 [cited by examiner]
US 20110059085A1 · Kim · 2011 [cited by applicant]
US 20180153991A1 · Barnett et al. · 2018 [cited by applicant]
CL 2016001977 · 2016 [cited by applicant]
EP 03030088A2 · 1989 [cited by applicant]
EP 0345543B1 · 1989 [cited by applicant]
EP 3150629A2 · 2017 [cited by applicant]
RU 2191031C2 · 2002 [cited by applicant]
WO 8602362 · 1986 [cited by applicant]
WO 2009140236A2 · 2009 [cited by applicant]
Gautam et al (Biotechnology Advances vol. 29, pp. 840-849) (Year: 2011). [cited by examiner]
Barratt-Due et al., Polyvalent Immunoglobulin Significantly Attenuated the Formation of IL-1 (beta) in [cited by applicant]
Cesena, et al., Immune-modulation by polycylonal IgM treatment reduces atherosclerosis in hypercholesterolemic apoE-/-mice, Atherosclerosis, 220, pp. 59-65, 2012. [cited by applicant]
Hurez, et al., Pooled Normal Human Polyspecific IgM Contains Neutralizing Anti-Idiotypes to IgG Autoantibodies of Autoimmune Patents and Protects from Experimental Autoimmune Disease, Blood, vol. 90, No. 10, 1997, pp. 4… [cited by applicant]
Kreymann et al., Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock, Critical Care Medicine, 2007, vol. 35, No. 12, pp. 2677-2685. [cited by applicant]
Linevsky et al., IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes, Am. J. Physiol. Gastrointest. Liver Physiol., 273: G1333-G1340, 1997. [cited by applicant]
Massironi et al., Minimal Concentration of Human IgM and IgG Antibodies Necessary to Protect Mice from Challenges with Live O6 [cited by applicant]
Oesser et al., Protective capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia, Res. Exp. Med., vol. 198, pp. 325-339, 1999. [cited by applicant]
Rossmann et al., In Vitro and In Vivo Activity of Hyperimmune Globulin Preparations Against Multiresistant Nosocomial Pathogens, Infection, 2014, pp. 169-175, vol. 43, No. 2. [cited by applicant]
Sun et al., Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-a by macrophages, Microbial Pathogenesis, 16:298-305, 2009. [cited by applicant]
Tatum, Large scale recovery of biologically active IgM (95% pure) from human plasma obtained by therapeutic plasmapheresis, Journal of Immunological Methods, vol. 158, pp. 1-4, 1993. [cited by applicant]
Tramont et al., Progress in the development of an HIV vaccine, Expert Opinion on Emerging Drugs, vol. 8, No. 1, pp. 37-45, 2003. [cited by applicant]
Wand et al., IgM-Enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in early Severe Sepsis: A Before-After Cohort Study, PLOS One, 2016, pp. 1-13, vol. 11, No. 8. [cited by applicant]
Norby-Teglund et al, Intravenous Polyclonal IgM-Enriched immunoglobulin Therapy in Sepsis: A Review of Clinical Efficacy in Relation to Microbiological Aetiology and Severity of Sepsis, Journal of Internal Medicine, 200… [cited by applicant]
Mahassni et al., Purification of a Murine IgM Monoclonal Antibody, Hybridoma, vol. 28, No. 3, 2009, pp. 189-197. [cited by applicant]
Gagnon et al., Purification of IgM Monoclonal Antibodies, BioPharma, 2008, pp. 1-10. [cited by applicant]
Extended European Search Report, dated Mar. 17, 2017, in European Patent Application No. 16179975.4, 11 pages. [cited by applicant]
Chilean Office Action, dated Jan. 17, 2018, in corresponding Chilean Patent Application No. 2016-0176. [cited by applicant]
Kamran Mousavi Hosseine, et al., Preparation of Enriched Immunoglobulin M and Immunoglobulin A from Human Plasma, Medical Journal of Islamic Republic of Iran, vol. 17, No. 4, Winter 1382, Feb. 2004, pp. 315-318. [cited by applicant]
Sharad P. Adekar et al;, A Natural Human IgM Antibody that Neutralizes Botulinum Neurotoxin in vivo, Hybridoma, vol. 27, No. 2, Apr. 1, 2008, pp. 65-69. [cited by applicant]
European Patent Office Search Report mailed Jan. 13, 2017 in reference to co-pending European Patent Application No. 16180425.7. [cited by applicant]
Nair et al., Impact of [cited by applicant]
Norrby-Teglund et al., Relative Neutralizing Activity in Polyspecfic IgM, IgA and IgG Preparations against Group A Streptococcal Superantigens; Clinical Infectious Diseases, pp. 1175-1182, 2000. [cited by applicant]
Adekar et al., A Natural Human IgM Antibody that Neutralizes Botulinum Neurotoxin in vivo; Hybridoma 27(2) pp. 65-69, 2008. [cited by applicant]
European Office Action, dated Apr. 19, 2018, in corresponding European Patent Application No. 16179975.4 (33 pages). [cited by applicant]
Chilean Search Report, in corresponding Chilean Patent Application No. 2016-001977 (7 pages). [cited by applicant]
A. Marcuzzi et al, “Effects of anti-IgM suppression on polyclonally activated murine B cells: analysis of immunoglobulin mRNA, gene specific nuclear factors and cell cycle distribution”, Nucleic Acids Research, Dec. 25,… [cited by applicant]
M. P. Horn et al: “Preclinical In Vitro and In Vitro Characterization of the Fully Human Monoclonal IgM Antibody KBPA101 Specific for Pseudomonas aeruginosa Serotype IATS-O11”, Antimicrobial Agents and Chemotherapy, vol… [cited by applicant]
C. Weyand et al: “Administration in vivo of recombinant interleukin 2 protects mice against septic death.”, Journal of Clinical Investigation, vol. 79, No. 6, Jun. 1, 1987, pp. 1756-1763. [cited by applicant]
A.J. Walpen, et al., “Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum.” Xenotransplantation, 2004, vol. 11, Issue 2, pp… [cited by applicant]
M. Trautmann, et al., “Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an Ig-M enriched product.” Clinical & Experimental Immunology, … [cited by applicant]
S. Takasu et al; Today's Therapy; 2002; pp. 149-150; vol. 44. [cited by applicant]
Patrone et al: TNF-Independent IL-8 Expression: Alterations in Bacteria Challenge Dose Cause Differential Human Monocytic Cytokine Response, J Immunol 2006; 177:1314-1322. [cited by applicant]
Pomorska-Mol et al (Journal of Immunology Research vol. 2020, Article ID 2614317, pp. 1-7) (Year: 2020). [cited by applicant]